Aurobindo Pharma shares fell nearly 5% to ₹1,039 amid reports it may acquire Zentiva for $5-5.5 billion. This would be the largest acquisition by an Indian pharma company, enhancing its European presence, though Aurobindo clarified no definitive agreement has been made yet.
